Patents by Inventor Marna Williams

Marna Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
    Publication number: 20220403033
    Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.
    Type: Application
    Filed: February 3, 2022
    Publication date: December 22, 2022
    Applicant: GENENTECH, INC.
    Inventors: Banmeet Anand, Eric Stefanich, Meina Tang, Jennifer Visich, Marna Williams, Sharon O'Byrne
  • METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
    Publication number: 20210238288
    Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.
    Type: Application
    Filed: February 4, 2020
    Publication date: August 5, 2021
    Applicant: GENENTECH, INC.
    Inventors: Banmeet Anand, Eric Stefanich, Meina Tang, Jennifer Visich, Marna Williams, Sharon O'Byrne
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20200031929
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: October 10, 2019
    Publication date: January 30, 2020
    Inventors: Marna WILLIAMS, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 10442859
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 15, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20160002335
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Inventors: Marna WILLIAMS, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 9175081
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: November 3, 2015
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
    Publication number: 20140120084
    Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.
    Type: Application
    Filed: September 24, 2013
    Publication date: May 1, 2014
    Applicant: GENENTECH, INC.
    Inventors: Banmeet Anand, Eric Stefanich, Meina Tang, Jennifer Visich, Marna Williams, Sharon O'Byrne
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20140065063
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: May 15, 2013
    Publication date: March 6, 2014
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8461306
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 11, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8444980
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 21, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8445646
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 21, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8436146
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 7, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8349330
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: January 8, 2013
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120070440
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 22, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064083
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: June 30, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064068
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064067
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064069
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna WILLIAMS, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Llu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8133981
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 13, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8088898
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: January 3, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu